Lymphodepleting chemotherapy

DRUG17 trials

Sponsors

Inge Marie Svane, Novartis Pharmaceuticals, Century Therapeutics, Inc., Patrick C. Johnson, MD, Washington University School of Medicine

Conditions

Advanced/Metastatic NSCLCAggressive B-cell NHLAggressive Non-Hodgkin LymphomaBreast Cancer (Locally Advanced or Metastatic)C-MYC/BCL2 Double-Hit High-Grade B-Cell LymphomaC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaClear Cell CarcinomaColorectal Cancer

Phase 1

Vemurafenib and TIL Therapy for Metastatic Melanoma

CompletedNCT02354690

Inge Marie SvaneMetastatic Melanoma

Start: 2014-11-30End: 2018-12-31Updated: 2020-03-23

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

TerminatedNCT05336409

Century Therapeutics, Inc.Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, R/R CD19-Positive B-Cell Malignancies

Start: 2023-01-24End: 2025-07-01Updated: 2025-12-18

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

RecruitingNCT06185751

Washington University School of MedicineMultiple Myeloma

Start: 2024-08-22End: 2040-08-31Target: 25Updated: 2026-03-11

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Active, not recruitingNCT06255028

Century Therapeutics, Inc.Diffuse Cutaneous Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Lupus Nephritis +1

Start: 2025-02-06End: 2028-08-31Updated: 2026-01-08

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

RecruitingNCT06358430

M.D. Anderson Cancer CenterColorectal Cancer, Minimal Residual Disease

Start: 2024-12-02End: 2029-01-18Target: 42Updated: 2026-01-15

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

RecruitingNCT07061938

Acepodia Biotech, Inc.IgG4 Related Disease

Start: 2026-01-01End: 2027-06-20Target: 30Updated: 2026-02-13

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

RecruitingNCT07072234

M.D. Anderson Cancer CenterClear Cell Carcinoma, Growth Factor, Phase 1

Start: 2025-09-25End: 2030-02-01Target: 30Updated: 2025-10-07

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

RecruitingNCT07467863

Beijing BiotechAdvanced/Metastatic NSCLC, Non-Small Cell Lung Cancer

Start: 2026-02-02End: 2028-02-17Target: 48Updated: 2026-03-12

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

RecruitingNCT07480213

Beijing BiotechRelapsed/Refractory SCLC, SCLC, Extensive Stage, Small Cell Lung Cancer (SCLC)

Start: 2026-02-02End: 2028-04-17Target: 60Updated: 2026-03-18

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

RecruitingNCT07480954

Beijing BiotechEpithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma +1

Start: 2026-02-04End: 2028-05-17Target: 36Updated: 2026-03-18

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

RecruitingNCT07486089

Beijing BiotechBreast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)

Start: 2026-02-02End: 2028-03-17Target: 60Updated: 2026-03-20

Phase 2

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

CompletedNCT02445248

Novartis PharmaceuticalsDiffuse Large B-cell Lymphoma (DLBCL)

Start: 2015-07-29End: 2022-12-22Updated: 2024-04-18

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

CompletedNCT03610724

Novartis PharmaceuticalsNon-Hodgkin Lymphoma

Start: 2019-02-15End: 2023-04-26Updated: 2024-06-20

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, not recruitingNCT05583149

Patrick C. Johnson, MDAggressive B-cell NHL, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma +10

Start: 2023-03-01End: 2029-03-01Updated: 2026-01-29

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Not yet recruitingNCT07316010

M.D. Anderson Cancer CenterLarge B-cell Lymphoma

Start: 2026-06-01End: 2031-03-21Target: 10Updated: 2026-03-20

Phase 3

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Active, not recruitingNCT05888493

Novartis PharmaceuticalsFollicular Lymphoma (FL)

Start: 2023-10-02End: 2031-02-20Updated: 2026-03-24

Unknown Phase

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

Not yet recruitingNCT07314567

Tongji HospitalSystem Lupus Erythematosus(SLE)

Start: 2026-01-01End: 2027-12-31Target: 22Updated: 2026-01-02

Related Papers

Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).

Journal of Clinical Oncology2026-01-10

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

2025-11-181 citations

Deep learning-based image analysis of pretreatment FDG-PET/CT predicts CAR-T cell treatment outcome at month-12 for patients with Relapsed/Refractory large B-cell lymphomas

Blood2025-11-03

Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.

Journal of Clinical Oncology2024-06-019 citations

Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study

Blood2023-11-0215 citations

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Blood2023-11-021 citations

Are Pivotal CART Trials Representative of Population at Risk?

Blood2023-11-02

The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.

Journal of Clinical Oncology2023-06-014 citations

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Cancer Discovery2023-05-30107 citations

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood2022-11-1522 citations

612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis

Regular and Young Investigator Award Abstracts2022-11-01

ANÁLISE DAS REAÇÕES ADVERSAS AO TISAGENLECLEUCEL: UMA REVISÃO DOS PRINCIPAIS ESTUDOS CLÍNICOS

Hematology Transfusion and Cell Therapy2022-10-01

S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY

HemaSphere2022-06-014 citations

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)

HemaSphere2022-06-01

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Experimental Hematology and Oncology2022-03-2525 citations

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blood2022-02-15130 citations

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

Blood Advances2022-01-1420 citations

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood2021-11-0511 citations

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

2021-09-10407 citations

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

Blood Advances2021-08-2528 citations

44 more papers not shown